Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
Hospices Civils de Lyon, Hematology, Lyon-Sud Hospital, Pavillon Marcel Bérard, France
Abstract: Monoclonal antibodies are likely to make a considerable contribution in the treatment of acute lymphoblastic leukemia (ALL). High expression of CD22 antigen is found on the surface of leukemia cells in ALL. Inotuzumab ozogamicin, a CD22 monoclonal antibody conjugated to calicheamicin, which has shown efficacy in patients with lymphomas, has also shown encouraging activity in relapsed or refractory ALL with a high morphologic and molecular response rate. This article summarizes the current approaches to treating ALL with inotuzumab ozogamicin, based on available data from the literature.
Keywords: monoclonal antibody, inotuzumab ozogamicin, CMC-544, acute lymphoblastic leukemia, targeted therapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]